Amgen's Multiple Myeloma Drug Shows Promise in Phase 3 Trial - Presented by: The Aol. On Network

Shares of Amgen are moving higher on Monday. The drug maker is seeing great signs in the development of treatment for multiple myeloma, a bone marrow cancer.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
MSFT $ 42.515 4.50 ▼ 9.56%
BAC $ 15.56 0.29 ▼ 1.83%
INTC $ 34.215 1.59 ▼ 4.44%
AAPL $ 111.1896 1.91 ▼ 1.69%
QQQ $ 102.06 2.08 ▼ 2.00%
SIMG $ 7.265 1.37 ▲ 23.14%
FCX $ 18.23 1.33 ▼ 6.80%
PFE $ 33.20 0.40 ▲ 1.22%

As of 1/27/2015, 10:05 AM
More Most Active